Abstract The mechanism(s) by which iron in blood is transported across the blood-brain barrier (BBB) remains controversial. Here we have examined the first step of this trans-cellular pathway, namely the mechanism(s) of iron uptake into human brain microvascular endothelial cells (hBMVEC). We show that hBMVEC actively reduce non-transferrin bound Fe III (NTBI) and transferrin-bound Fe III (TBI); this activity is associated with one or more ferrireductases. Efficient, exo-cytoplasmic ferri-reduction from TBI is dependent upon transferrin receptor (TfR), also. Blocking holo-Tf binding with an anti-TfR antibody significantly decreases the reduction of iron from transferrin by hBMVEC, suggesting that holo-Tf needs to bind to TfR in order for efficient reduction to occur. 
Abstract The mechanism(s) by which iron in blood is transported across the blood-brain barrier (BBB) remains controversial. Here we have examined the first step of this trans-cellular pathway, namely the mechanism(s) of iron uptake into human brain microvascular endothelial cells (hBMVEC). We show that hBMVEC actively reduce non-transferrin bound Fe III (NTBI) and transferrin-bound Fe III (TBI); this activity is associated with one or more ferrireductases. Efficient, exo-cytoplasmic ferri-reduction from TBI is dependent upon transferrin receptor (TfR), also. Blocking holo-Tf binding with an anti-TfR antibody significantly decreases the reduction of iron from transferrin by hBMVEC, suggesting that holo-Tf needs to bind to TfR in order for efficient reduction to occur. Ferri-reduction from TBI significantly decreases when hBMVEC are pre-treated with Pt II , an inhibitor of cell surface reductase activity. Uptake of 59 Fe from 59 Fe-Tf by endothelial cells is inhibited by 50 % when ferrozine is added to solution; in contrast, no inhibition occurs when cells are alkalinized with NH 4 Cl. This indicates that the iron reduced from holo-transferrin at the plasma membrane accounts for at least 50 % of the iron uptake observed. hBMVECdependent reduction and uptake of NTBI utilizes a Pt Iron, while required for several normal physiological processes, can be duplicitous in nature. Iron's innate ability to accept and donate electrons is vital for cellular processes such as mitochondrial energy generation, myelination, neurotransmission, oxygen transport, and cellular division (Salvador 2010; Madsen and Gitlin 2007) . A disruption in the normal redox chemistry of brain iron can be detrimental to normal function. Improper iron regulation by cells of the brain has been linked to neurological disorders such as Alzheimer's and Parkinson's disease (Madsen and Gitlin 2007; Rivera-Mancía et al. 2010) . To fully understand the pathology of these neurological diseases, we need to fully understand the mechanisms of iron transport into the brain, the cellular distribution/ regulation of iron in the brain parenchyma and the mechanism(s) of iron efflux out of the central nervous system (CNS). Here, we focus in on the first of these steps; iron uptake by the capillary endothelial cells (EC) of the blood brain barrier (BBB). The BBB is a unique entity which consists of microvascular endothelial cells (MVEC), glial cells, and pericytes all of which are thought to act as a single unit to protect the brain from harmful polar molecules. The endothelial cells of the BBB possess tightjunctions while lacking the fenestrations common to EC in the periphery; therefore, solutes in the blood must be transported transcellulary into the brain (Rouault and Cooperman 2006; Abbott et al. 2006) .
Iron in the blood is coordinated to small molecule ligands such as citrate (Königsberger et al. 2000) (nontransferrin bound iron, NTBI) or to the iron transport protein Tf (transferrin bound iron, TBI). For endothelial cells to acquire iron from either TBI or NTBI, a luminal uptake mechanism must exist. Typically, uptake of TBI occurs when holo-Tf binds its receptor, followed by the release and reductase-dependent reduction of TBI in the endosome; this Fe II is then exported from the endosome through a divalent cation transporter such as divalent metal transporter 1 (DMT1) (Rouault and Cooperman 2006; Garrick 2011) . Previous studies have demonstrated the expression and co-localization of the iron-related transport proteins DMT1 and TfR in the brain microvasculature (Burdo et al. 2001; Yang et al. 2010; Siddappa et al. 2002) , although the expression of DMT1 is controversial (Moos et al. 2007) . A thorough examination of the divalent cations which act either as substrate or competitor of DMT1-mediated transport, has been reported (Garrick et al. 2006a (Ohgami et al. 2006; Tulpule et al. 2010 ). Both of these ferrireductases catalyze the transport of electrons from cytosolic reductants [ascorbate or NAD(P)H] to extracellular or endosomal Fe III (Ohgami et al. 2006; Atanasova et al. 2004) . However, there are no literature reports demonstrating expression or functional reductase activity of either Dcytb or STEAP2 in brain MVEC (BMVEC).
To investigate the uptake mechanism(s) associated with EC accumulation of Fe from TBI and NTBI, we used monolayers of a human brain microvascular endothelial cell line (hBMVEC). Using this model system we examined the expression of iron-related transport proteins and their roles in iron reduction and uptake. We distinguish between TBI and NTBI reduction and assess the divalent metal ion uptake kinetic properties of the divalent cation transporter(s) in hBMVEC.
Materials and methods
Cell culture hBMVEC were a generous gift from Dr. Supriya Mahajan at the Center for Innovation, Buffalo, NY. hBMVEC and Caco-2 cells were cultured in RPMI 1640 containing 19 MEM amino acids, 19 MEM vitamins (Mediatech Inc, Manassas, VA), 10 % FBS (Gemini Bio-products, West Sacramento, CA), 10 % NuSerum (BD Biosciences, Bedford, MA), 25 mM HEPES (Thermo Fisher Scientific, Waltham, MA), penicillin (100 U/mL), streptomycin (100 U/mL), 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO), 1 mM sodium pyruvate, heparin (5 U/mL) (Alfa Aesar, Ward Hill, MA), and NaHCO 3 , pH 7.4. Cells were incubated in a humidified incubator at 37°C, 5 % CO 2 . The culture medium was replaced every other day and cells were passaged weekly. All experiments were performed in 24-well tissue culture dishes unless otherwise specified. Experiments were performed between passage 4 and 8 when cells reached approximately 90-95 % confluency.
Indirect immunofluorescence
All indirect immunofluorescence incubations involved gentle agitation. Monolayers were washed 39 with 1 ml of phosphate-buffered saline (PBS) solution. The cells were then fixed for 10 min at room temperature (RT) with 3.7 % formaldehyde, and washed 49 with PBS (5 min/wash). Non-specific binding sites were blocked with 3 % bovine serum albumin (BSA) (EMD Chemicals, Darmstadt, Germany) in PBS at RT for 90 min. Cells were then incubated with primary antibody (1:1000 dilution of goat polyclonal antihuman TfR antibody (R&D Systems, Minneapolis, MN), mouse monoclonal anti-human VWF antibody, or goat polyclonal anti-STEAP2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)) in 3 % BSA in PBS over-night (O/N) at 4°C. Cultures were then washed 39 with PBS, after which cells were incubated with secondary antibody (1:3,000 dilution of Alexa Fluor 488 donkey anti-goat IgG (Life Technologies, Grand Island, NY) (TfR & STEAP2), or Cy5 conjugated rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) (VWF)) in 3 % BSA in PBS at RT for 1 h in the dark. The cells were then washed 39 with PBS in the dark at RT, after which they were imaged. Images were obtained using a Zeiss Axio Observer inverted microscope, 409 magnification and Zeiss AxioVision software (Zeiss, Thornwood, NY). The captured images were adjusted for brightness and contrast using Adobe Photoshop 7.0 software.
Immunoblots
Membrane proteins from Caco-2 and hBMVEC were separated from the cellular protein pool as follows. Cells were removed from 100 mm tissue culture dishes, washed 29 with PBS, and were pelleted. The cell pellet was resuspended with membrane purification buffer (50 mM Tris, 150 mM NaCl, pH 7.4) in a 5:1 ratio of buffer to pellet. Protease inhibitors were added to the cell suspension and the cells were cracked open by 3 rapid freeze-thaw cycles in liquid nitrogen and ice, respectively. The cell suspension was then centrifuged at 14,0009g for 30 min at 4°C. The supernatant was removed leaving only membranes and membrane proteins in the pellet. This fraction was resuspended with a 1:1 ratio of mammalian lysis buffer plus protease inhibitors (100 mM HEPES, pH 7.4, 0.5 % (v/v) IGEPAL) to pellet and was stored O/N at 4°C. For whole cell lysates, confluent monolayers of cells were lysed with mammalian lysis buffer plus protease inhibitors for 1 h 37°C 5 % CO 2 110 rpm. Protein content was quantified and equal amounts of protein were run in each well of a 10 % SDS-PAGE for 20 min at 109 V followed by 180 V until the front ran off the gel. Proteins were transferred onto a PVDF membrane at 0.15 amps for 75 min using a semi-dry transfer apparatus. The PVDF membranes were blocked with 5 % BSA in TBST for 1 h at 4°C. Membranes were then incubated with primary antibody (1:10,000 dilution of mouse monoclonal anti-DMT1 antibody (Acris Antibodies, San Diego, CA), 1:5,000 dilution of goat polyclonal anti-STEAP2 antibody, or 1:5,000 dilution of rabbit polyclonal anti-human Dcytb antibody (Acris Antibodies, San Diego, CA)) in TBST O/N at 4°C. The anti-DMT1 antibody is specific for exon 2 so it is not isoform-specific. Membranes were washed for 1 h then incubated with secondary antibody (0.3 ll/ml of goat anti-rabbit IgG-HRP or donkey anti-goat IgG-HRP (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in TBST 3 % BSA for 1 h at RT. Membranes were washed for 1 h with TBST and then processed in a dark room using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA) as per instructed. Films were scanned and the captured images were adjusted for brightness and contrast using Adobe Photoshop 7.0 software.
Pt
II cytotoxicity assay All assays were performed using CytoTox 96 NonRadioactive Cytotoxicity Assay from Promega (Promega Corporation, Madison, WI) as per instructions.
Briefly, experiments were performed in triplicate under conditions mimicking the ferrozine assay. After a 3.5 h incubation, the supernatants were collected and assayed for LDH content. Percent cytotoxicity is calculated by dividing experimental LDH levels by total LDH times one hundred.
Colorimetric-based ferrozine assay for Fe II All assays were performed with a total working volume of 150 ll shaking at 100 rpm in a 37°C 5 % CO 2 humidified incubator. We used a physiological incubation buffer (PIB) for all assays (25 mM MOPS, 25 mM MES, 5.4 mM KCl, 5 mM glucose, 140 mM NaCl, 1.8 mM CaCl 2 , 800 lM MgCl 2 , pH 7.0). Final working concentrations of reagents (unless otherwise specified) were as follows: 10 lg/ml TfR-Ab, 25 lM Holo-Tf (EMD Chemicals, Darmstadt, Germany), 100 lM potassium tetrachloroplatinate II (Pt II ) (Alfa Aesar, Ward Hill, MA), 100 lM FeCl 3 (Thermo Fisher Scientific, Waltham, MA), and 250 lM Citrate, 1 mM ferrozine, 250 lM apo-Tf from Sigma-Aldrich, St. Louis, MO. Each assay contained ferrozine and citrate (unless noted otherwise), plus the reagents indicated in the respective graph. All pre-incubations were conducted for 30 min after which the cells were washed with PBS and assay reagents were added and incubated for 3 h. After the 3 h incubation the PIB was collected and 50 ll was transferred to a 96-well plate. Absorbance readings were taken at 562 nm using a FLUOstar Omega spectrophotometer (BMG Labtech, Cary, NC) corrected for a blank of PIB containing identical reagents and incubation procedures minus cells. Cells were washed, lysed, and their protein content quantified. Experimental absorbance readings were extrapolated onto a ferrozine-Fe II standard curve was used to convert experimental absorbance reading into the amount of Fe II present in solution. These values were normalized for protein content. 59 Fe-transferrin loading procedure
The loading of 59 Fe onto Tf was performed as previously described (Burdo et al. 2003 ) with modifications. Briefly, using Tf-loading buffer (0.1 M HEPES, pH 7.5, 0.15 M NaCl), 20 mM NaHCO 3 , 21.3 mM NTA, 44 lM 59 Fe, and 20 lM apo-Tf we did the following. 59 Fe was incubated with Tf-loading buffer containing NaHCO 3 and NTA for 5 min at RT after which apo-Tf was added and incubated for 2 h at RT. This 59 Fe-Tf solution containing non-Tf bound 59 Fe was buffer exchanged using a Nanosep 10 K MWCO Omega spin column (PALL Corporation, Port Washington, NY) 3 9 10 min at 5,500 rpm. This procedure yielded a 59 Fe-Tf purity of [95 %. 59 Fe uptake assays
All assays were performed in a 24-well tissue culture dish with a total working volume of 150 ll. 59 Fe was kept in a reduced state by incubation with 2 mM ascorbate throughout the assay. This was done to make 59 Fe uptake reductase independent.
Quantification of protein concentration
The protein content of Caco-2 and hBMVEC were determined according to the method described by (Bradford (1976) using BSA as the standard.
Results

Identification of iron transport proteins in cultured hBMVEC
To begin our analysis of the iron-related proteins expressed by hBMVEC we confirmed the expression of both DMT1 and TfR. Using an immunoblot containing proteins purified from the membranes of both Caco-2 and hBMVEC, we probed for DMT1 with an antibody that is specific for exon 2 and found a strong band at *62 kDa (Fig. 1e) . Using indirect immunofluorescence, we found that TfR in hBMVEC was plasma membrane-associated (Fig. 1a) ; our relatively low-resolution epifluorescence images precluded our visualizing endosomal TfR. Von-Willebrand factor (VWF), an endothelial cell-specific protein, was used as a marker for hBMVEC (Fig. 1b) .
Next, we examined the expression of ferrireductases in hBMVEC. Probing for Dcytb via immunoblot, we identified Dcytb immunoreactive protein of *40 kDa in both hBMVEC and Caco-2 cells as positive control (Fig. 1e) . Strong bands were also identified at *48 kDa when probed with an anti-STEAP2 antibody (Fig. 1e) . We used indirect immunofluorescence to probe the sub-cellular localization of STEAP2 in hBMVEC and found the protein to localize to the plasma membrane (Fig. 1c) ; again our relatively low-resolution epifluorescence images precluded our visualizing endosomal STEAP2. Plasma membrane localization of STEAP2 occurs in cells expressing the endothelial cell-specific marker VWF (Fig. 1d) . Full-length western blots displayed little to no background when using antibodies from Fig. 1e , indicating a high degree of specificity ( Supplementary  Fig. 1 ). These data present novel evidence for the expression of the ferrireductases STEAP2 and Dcytb in hBMVEC.
Reduction of iron from Tf is dependent upon citrate and TfR
Monolayers of hBMVEC were incubated with holoTf, ferrozine, and increasing amounts of citrate. Increasing the citrate concentration yielded an increased reduction of iron from Tf as measured by the formation of ferrozine-Fe II complex (Fig. 2a) . The inhibition of Tf, TfR interactions at the hBMVEC surface by either anti-TfR antibody or tenfold excess of apo-Tf significantly inhibited the reduction of iron from Tf (Fig. 2b, c respectively) . These data show that hBMVEC can reduce iron from Tf and this hBMVECdependent reduction is dependent upon citrate concentration and the interaction of Tf with endogenous TfR.
Cell-surface ferrireductases are required for the hBMVEC-dependent reduction of TBI and NTBI We used Pt II , an inhibitor of pyridine nucleotidedependent reductases (Armarego and Ohnishi 1987) including cell-surface ferrireductases (Eide et al. 1992) , to assess the relative contributions of ferrireductases in mediating the reduction of TBI and NTBI. Dose-response experiments indicated that 100 lM Pt II exihibited minimal cytotoxicity in hBMVEC monolayers (Supplementary Table 1 ) while displaying maximal effectiveness in inhibition of ferrireduction by hBMVEC (data not shown). The addition of 100 lM Pt II to the hBMVEC monolayer significantly inhibited reduction of iron from Tf (Fig. 3a) . In contrast, the addition of 100 lM Pt II did not significantly inhibit the reduction of NTBI (Fig. 3b) . Fig. 1 TfR, DMT1, STEAP2, and Dcytb expression in hBMVEC. Indirect immunofluorescence was carried out using hBMVEC monolayers. Co-immunofluorescence yields localization of both TfR and VWF to the plasma membrane (a and b, respectively) (409 magnification). The same is true for STEAP2 and VWF (c and d, respectively) (409 magnification). Immunoblot's were carried out with proteins purified from the membranes (DMT1) or from whole cell lysates (STEAP2 & Dcytb) of the respective cell types as indicated (e). Antibodies used are as indicated to the left of the blots and size in kDa to the right hBMVEC can accumulate 59 Fe from TBI and NTBI
Fe
II released and reduced from Tf or exogenous ligand (e.g. citrate) is likely substrate for hBMVEC divalent cation transporter(s) at the plasma membrane. We monitored the uptake of iron into hBMVEC through the use of the radionuclide 59 Fe using either -citrate as substrate (reductase-independent uptake conducted in the presence of 2 mM dihydroascorbate). Under these conditions, hBMVEC accumulate iron with a K M = 3.9 ± 1.1 lM (Fig. 4a) FeTf by ferrireduction. In this assay, ferrozine inhibited reductase-dependent iron uptake by approx. 50 % (Fig. 4b) .
Pt II was used to correlate ferrireductase inhibition with iron uptake inhibition. Uptake of 59 TBI by hBMVEC was quantified in the presence of Pt II (Fig. 4c) NTBI uptake by hBMVEC. The data from Fig. 4d parallel our reductase assay results given in Fig. 3b .
Acidification is not required for the accumulation of TBI by hBMVEC
To assess the contribution made by canonical TfR cycling we performed alkalinization assays. Alkalinization Fig. 2 Reduction of TBI is dependent upon citrate concentration and Tf-TfR interaction. The hBMVEC-dependent formation of Fe II species were quantified using colorimetric ferrozine assays. Each sample was blank corrected with a minus hBMVEC control and normalized for protein concentration. Monolayers of hBMVEC were incubated with TBI, ferrozine, and either increasing concentrations of citrate (a), anti-TfR antibody (b), or tenfold apo-Tf (250 lM) (c). (b, c) contained a constant citrate concentration. n = 3 for each result in each panel. Data are mean ± standard deviation (SD). ***P-value \0.0001 as analyzed by the paired t-test Fig. 3 Reduction of TBI and NTBI is dependent upon hBM-VEC-surface ferrireductases. Colorimetric ferrozine assays were used to quantify the formation of Fe II species in solution. Each sample was blank corrected with a minus hBMVEC control and normalized for protein concentration. Potassium tetrachloroplatinate II (100 lM) was used to inhibit reductase activity by hBMVEC. Substrates were either TBI (a) or NTBI (b). Values are mean ± SD (a, n = 12; b, n = 3). ***P-value B0.0001 as analyzed by the paired t-test assays using NH 4 Cl inhibit proton accumulation in the endosomes, thus minimizing the proton-dependent mobilization of TBI and subsequent accumulation of iron. The data from the NH 4 Cl alkalinization assay are depicted in Fig. 4e Fe II concentrations; IC 50 = 4.3 ± 1.2 lM and 8.4 ± 2.5 lM (Fig. 5a, b accumulation by *50 % with an IC 50 = 3.1 ± 0.7 lM (Fig. 5c) . By quantifying this competition in the presence of both divalent cations we tested the hypothesis that two separate divalent cation transporters were functioning in hBMVEC, one specific for Mn II , the other specific for Zn II . However, inclusion of Mn II and Zn II together at 50 lM each in the uptake buffer resulted in the equivalent 50 % inhibition of 59 Fe II accumulation seen with either metal ion alone (Fig. 5d) .
Discussion
The identification of the major iron transport proteins in hBMVEC is required for an understanding of the Data are mean ± SD. *P-value B0.01 as analyzed by the unpaired t-test mechanisms regulating TBI and NTBI uptake at the BBB. Both TfR and DMT1 have been identified in rat brain microvessels by indirect immunofluorescence (Burdo et al. 2001 ). These workers also showed TfR and DMT1 co-localization in this tissue. Figure 1 corroborates this report regarding the expression of both TfR and DMT1 by the brain microvasculature. Further investigation using confocal microscopy would provide the necessary resolution to localize these proteins to specific hBMVEC compartments although our lower-resolution images do indicate their expression at the PM.
The reduction of Fe III in Tf, and thus Fe dissociation, requires an increase in the reduction potential (E°) of Fe III in the Fe III -Tf complex which is \-500 mV at pH 7 (Kraiter et al. 1998 ). The E°of TBI increases when 1) Tf associates with TfR, 2) an exogenous ligand is presented in solution (i.e. citrate), or 3) when the pH of the solution becomes more acidic. For example, upon Tf binding to TfR, the Fe III potential is increased by [200 mV (Dhungana et al. 2004) . Electron transfer from endogenous reductants (i.e. NADH) to TBI are thermodynamically favorable when the E°of TBI becomes more positive than the E°o f the endogenous reductants (Dhungana et al. 2004 ).
Cell-surface ferrireductases channel these reducing equivalents from intracellular reductants through the plasma membrane to TBI and NTBI. In relation to the STEAP family of metalloreductases, Steap2 is highly expressed in the brain and co-localizes with TfR; these observations make Steap2 a likely hBMVEC ferrireductase candidate (Ohgami et al. 2006) . Given the presence of STEAP2 (Ohgami et al. 2006) as well as Dcytb (Tulpule et al. 2010) transcripts in the brain, we assessed the expression of these two ferrireductases in hBMVEC specifically. The immunoblots (Fig. 1e) indicated that both Dcytb and STEAP2 are present in these cells. Redundancy in function is not unexpected for the BBB; there is evidence for such redundancy in Steap3 K/O mice which retain residual erythroid reductase activity (Ohgami et al. 2005) . We demonstrated also a plasma membrane localization of Steap2 in hBMVEC (Fig. 1c) (Weaver et al. 2010; Dhungana et al. 2004; Bates et al. 1967) . Citrate is a physiologically relevant ligand in the blood with reported concentrations ranging from 90 lM (Bradbury 1997; Gaasch et al. 2007 ) to 110 lM (Wolcott and Boyer 1948; Königsberger et al. 2000) . As Tf in the blood, at a concentration of 25 lM, is only 30 % saturated with Fe III the physiological ratio of Tf:citrate is roughly 1:13 (Vincent and Love 2011) . Upon titration with 250 uM citrate (Tf:citrate ratio of 1:10) a significant increase in the reduction of TBI by hBMVEC was observed (Fig. 2a) . At physiological concentrations the exogenous ligand citrate likely increases the E°of TBI allowing iron to be reduced from Tf by our hBMVEC (Fig. 2a) . In addition, the data in Fig. 2b , c are consistent with observations that the Tf, TfR interaction alters the coordination of the Fe III in such a way as to raise its E°a llowing for reduction (Dhungana et al. 2004) .
Next, we wanted to investigate the hypothesis that cell-surface ferrireductases are actively reducing TBI and/or NTBI. The Kaplan lab demonstrated that Fre1, a cell-surface ferrireductase found in Saccharomyces cerevisiae, is inhibited by Pt II (Eide et al. 1992 ): Pt II had previously been demonstrated to inhibit pyridinenucleotide reductases likely by reaction with protein cysteine thiol(s) (Armarego and Ohnishi 1987) . We extended these observations regarding Pt II to our mammalian cell culture system and demonstrated that Pt II effectively inhibited cell-surface reduction of TBI (Fig. 3a) . In contrast, Pt II had no effect on NTBI reduction by hBMVEC (Fig. 3b) . We propose that in hBMVEC a Pt II -sensitive cell-surface ferrireductase is required for the reduction of TBI while a Pt II -insensitive one is responsible for Fe III reduction (and release) in NTBI. This apparent difference in reductase sensitivity to Pt II is under current investigation; note, however, that while Dcytb and the Steap proteins share ferrireductase activity, they are neither genetic nor structural homologs.
Since TBI and NTBI appear reduced at the cellsurface of hBMVEC, we hypothesized that the substrate for hBMVEC iron accumulation would be Fe II . To test this we conducted a reductase-independent NTBI 59 Fe II -uptake analysis with hBMVEC monolayers (Fig. 4a) . Our results indicate that hBMVEC accumulate 59 Fe II with a K M value *3.9 lM similar to the value for DMT1 expressed in HEK293 cells, *3 lM (Garrick et al. 2006a (Fig. 3a) . The residual 59 Fe accounted for in the presence of Pt II is consistent with what is seen when ferrozine is present (Fig. 4b) . Taken together, when ''cell-associated '' 59 Fe is accounted for, these data indicate that Pt II inhibits 59 TBI uptake in hBMVEC. We must assume that ''cell-associated'' 59 Fe also exists in our controls resulting in significantly less 59 Fe uptake in comparison to Fe II produced from reduction by hBMVEC. Thus, we infer from our data that Fe III reduction is not the rate-limiting step in iron accumulation by hBMVEC. This inference is consistent with the fact that overall Fe III reduction in 3 h was 3.5-fold greater than the corresponding 59 Feuptake in the same time period, or twofold greater if not accounting for residual ''cell-associated'' 59 Fe. In canonical Tf-TfR endosomal cycling, the dissociation and reduction of iron from Tf is partially mediated by endosomal acidification. Furthermore, transport of Fe II through DMT1 has a pH optimum of 5.5 and involves an inward proton current that is coupled to iron translocation (Gunshin et al. 1997) . With these facts in mind, we performed an alkalinization assay to determine if acidification contributes to the accumulation of iron by hBMVEC. The data in Fig. 4e demonstrate that an alkaline environment is not inhibitory to accumulation of iron from Tf indicating that cell-surface and/or endosomal acidification does not contribute the 59 Fe accumulation we observe. We conclude that canonical Tf-TfR endosomal cycling does not make a quantitatively significant contribution to the 59 TBI uptake in this cell system as this mechanism is enhanced by endosomal acidification Byrne et al. 2010 (Gunshin et al. 1997; Garrick et al. 2006a; Roth et al. 2002) . We assessed the activity of Mn II and Zn II as inhibitors of 59 Fe II uptake by hBMVEC. We demonstrated that the separate and simultaneous competition with each metal inhibited the accumulation of iron by hBMVEC by *50 % (Fig. 5a-d II transporter other than DMT1 contributes significantly to ferrous iron uptake by hBMVEC. One candidate for this activity is Zip14 which has been identified at the mRNA level in the CNS Girijashanker et al. 2008) . We are currently testing this hypothesis.
